You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Claims for Patent: 9,216,982

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,216,982

Title:	Certain chemical entities, compositions and methods
Abstract:	Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.
Inventor(s):	Ren; Pingda (San Diego, CA), Liu; Yi (San Diego, CA), Wilson; Troy Edward (San Marino, CA), Li; Liansheng (San Diego, CA), Chan; Katrina (Fremont, CA), Rommel; Christian (La Jolla, CA)
Assignee:	Intellikine LLC (La Jolla, CA)
Application Number:	14/296,953
Patent Claims:	1. A method of treating cancer in a subject, comprising administering to the subject an effective amount of a compound of formula: ##STR00676## or a pharmaceutically acceptable salt thereof, wherein the cancer is leukemia or lymphoma. 2. The method of claim 1, wherein the compound is: ##STR00677## or a pharmaceutically acceptable salt thereof. 3. The method of claim 1, wherein the cancer is leukemia. 4. The method of claim 3, wherein the leukemia is B-cell acute lymphoblastic leukemia (B-ALL), acute lymphocytic leukemia, hairy cell leukemia, myelodysplasia, myeloproliferative disorders, acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), or myelodysplastic syndrome (MDS). 5. The method of claim 1, wherein the cancer is chronic lymphocytic leukemia. 6. The method of claim 1, wherein the cancer is non-Hodgkin lymphomas. 7. The method of claim 1, wherein the cancer is acute lymphocytic leukemia (ALL). 8. The method of claim 1, wherein the cancer is diffuse large B-cell lymphoma. 9. The method of claim 1, wherein the cancer is myelodysplastic syndrome (MDS). 10. The method of claim 1, wherein the cancer is adult T-cell lymphoma. 11. The method of claim 1, wherein the cancer is acute myelogenous leukemia (AML). 12. The method of claim 1, wherein the cancer is chronic myelogenous leukemia (CML). 13. The method of claim 1, wherein the cancer is myeloproliferative disorders. 14. The method of claim 1, wherein the cancer is mast cell leukemia. 15. The method of claim 1, wherein the cancer is Hodgkin disease. 16. The method of claim 1, wherein the cancer is B-cell acute lymphoblastic leukemia. 17. The method of claim 1, wherein the cancer is T-cell acute lymphoblastic leukemia. 18. The method of claim 1, wherein the cancer is multiple myeloma (MM). 19. The method of claim 1, further comprising administering one or more second therapeutic agents selected from chemotherapeutic agents, cytotoxic agents, and radiation. 20. The method of claim 19, wherein the second therapeutic agent is an anti-CD20 antibody. 21. The method of claim 19, wherein the second therapeutic agent is rituximab. 22. The method of claim 19, wherein the second therapeutic agent is chlorambucil. 23. The method of claim 19, wherein the second therapeutic agent is chlorambucil, chlornaphazine, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, fludarabine, or cyclophosphamide. 24. The method of claim 1, wherein the cancer is lymphoma. 25. The method of claim 24, wherein the lymphoma is Hodgkin disease or non-Hodgkin lymphoma. 26. The method of claim 24, wherein the lymphoma is diffuse large B-cell lymphoma, small non-cleaved cell lymphoma, or adult T-cell lymphoma. 27. The method of claim 24, wherein the lymphoma is B-cell immunoblastic lymphoma. 28. The method of claim 19, wherein the second therapeutic agent is fludarabine, cyclophosphamide, or rituximab, or a combination thereof.

Details for Patent 9,216,982

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997	⤷ Try a Trial	2028-01-04
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002	⤷ Try a Trial	2028-01-04
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017	⤷ Try a Trial	2028-01-04
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.